Company intelligence / Profile preview
Actinobac Biomed, Inc.
Princeton, New Jersey, United States
- Ownership
- Private
- Employees
- ~2
- Development stage
- Other
01
Overview
Leukothera™, the lead candidate, has demonstrated synergistic anti-leukemia effects in vitro when combined with standard chemotherapeutic agents. The company’s approach may allow for lower doses of toxic drugs and reduced risk of resistance. The technology specifically targets malignant or inflammatory WBCs while sparing healthy cells.
- Therapeutic areas
- Infectious DiseasesImmunologyHematology
- Modalities
- natural biologicsprotein therapeutics (Leukothera™)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Foundation Venture Capital Group, LLCexclusive license from University of Medicine and Dentistry of New Jersey for core technology.
Beyond the preview
Go deeper on Actinobac Biomed, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Actinobac Biomed, Inc..